Clinical trial · Observational
Economic Evaluation of Innovative Molecular Analyses in Onco-haematology
Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the impact of innovative molecular diagnostics on the clinical management of patients with haematological malignancies via updated Appropriate-Prescribing-Guides including Next-Generation Sequencing (NGS) panels, facilitated therapeutic orientation, and optimised use of costly novel therapeutics and risk-adapted treatment. A micro-costing approach will be used to develop flat fee tarifs for NGS analyses.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Haematological Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (6)
- measure
- Percentage of Next Generation Sequencing (NGS) tests that have a clinical impact for the patient for five hematological malignancies.
- timeFrame
- 2 years
- measure
- Percentage of Next Generation Sequencing (NGS) that are from the oncologists internal to the platform versus external centres.
- timeFrame
- 2 years
- measure
- Average time in days between the Next Generation Sequencing (NGS) prescription being issued and the results being rendered to the clinician.
- timeFrame
- 2 years
- measure
- Percentage of prescriptions for diagnostics, prognostic, theranostics or treatment response
- timeFrame
- 2 years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with haematological malignancies referred for molecular diagnosis workup. RuBIH2 will focus on 5 clinical situations in onco-haematology: 1. Myelodysplasia (MDS) 2. Acute lymphocytic leukemia (T) (ALL) 3. Lymphoproliferative disorders (LPD) 4. Acute myeloblastic leukemia (AML) 5. Myeloproliferative disorders (MPD) Exclusion Criteria: * Other haematological diseases not included in the list above.
References
Publications (0)
Data not yet available